S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.69 (-0.03%)
AAPL   171.95 (-0.78%)
MSFT   421.16 (-0.06%)
META   488.67 (-1.05%)
GOOGL   151.05 (+0.12%)
AMZN   180.33 (+0.28%)
TSLA   175.57 (-2.37%)
NVDA   903.92 (+0.16%)
NIO   4.50 (-3.64%)
AMD   179.98 (+0.22%)
BABA   72.39 (+1.12%)
T   17.62 (+0.40%)
F   13.29 (+1.76%)
MU   117.81 (-1.12%)
CGC   8.54 (-10.58%)
GE   175.85 (-2.37%)
DIS   122.42 (+1.19%)
AMC   3.72 (-14.29%)
PFE   27.80 (+0.07%)
PYPL   66.99 (+0.63%)
XOM   116.20 (+1.07%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.69 (-0.03%)
AAPL   171.95 (-0.78%)
MSFT   421.16 (-0.06%)
META   488.67 (-1.05%)
GOOGL   151.05 (+0.12%)
AMZN   180.33 (+0.28%)
TSLA   175.57 (-2.37%)
NVDA   903.92 (+0.16%)
NIO   4.50 (-3.64%)
AMD   179.98 (+0.22%)
BABA   72.39 (+1.12%)
T   17.62 (+0.40%)
F   13.29 (+1.76%)
MU   117.81 (-1.12%)
CGC   8.54 (-10.58%)
GE   175.85 (-2.37%)
DIS   122.42 (+1.19%)
AMC   3.72 (-14.29%)
PFE   27.80 (+0.07%)
PYPL   66.99 (+0.63%)
XOM   116.20 (+1.07%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.69 (-0.03%)
AAPL   171.95 (-0.78%)
MSFT   421.16 (-0.06%)
META   488.67 (-1.05%)
GOOGL   151.05 (+0.12%)
AMZN   180.33 (+0.28%)
TSLA   175.57 (-2.37%)
NVDA   903.92 (+0.16%)
NIO   4.50 (-3.64%)
AMD   179.98 (+0.22%)
BABA   72.39 (+1.12%)
T   17.62 (+0.40%)
F   13.29 (+1.76%)
MU   117.81 (-1.12%)
CGC   8.54 (-10.58%)
GE   175.85 (-2.37%)
DIS   122.42 (+1.19%)
AMC   3.72 (-14.29%)
PFE   27.80 (+0.07%)
PYPL   66.99 (+0.63%)
XOM   116.20 (+1.07%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.69 (-0.03%)
AAPL   171.95 (-0.78%)
MSFT   421.16 (-0.06%)
META   488.67 (-1.05%)
GOOGL   151.05 (+0.12%)
AMZN   180.33 (+0.28%)
TSLA   175.57 (-2.37%)
NVDA   903.92 (+0.16%)
NIO   4.50 (-3.64%)
AMD   179.98 (+0.22%)
BABA   72.39 (+1.12%)
T   17.62 (+0.40%)
F   13.29 (+1.76%)
MU   117.81 (-1.12%)
CGC   8.54 (-10.58%)
GE   175.85 (-2.37%)
DIS   122.42 (+1.19%)
AMC   3.72 (-14.29%)
PFE   27.80 (+0.07%)
PYPL   66.99 (+0.63%)
XOM   116.20 (+1.07%)
NASDAQ:HLVX

HilleVax (HLVX) Stock Price, News & Analysis

$16.99
+1.37 (+8.77%)
(As of 03:52 PM ET)
Today's Range
$15.56
$16.99
50-Day Range
$14.15
$19.75
52-Week Range
$9.94
$20.22
Volume
85,595 shs
Average Volume
123,753 shs
Market Capitalization
$844.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.67

HilleVax MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
93.1% Upside
$30.67 Price Target
Short Interest
Healthy
3.20% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.18mentions of HilleVax in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$986.29 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.22) to ($3.38) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.77 out of 5 stars

Medical Sector

449th out of 939 stocks

Biological Products, Except Diagnostic Industry

67th out of 154 stocks

HLVX stock logo

About HilleVax Stock (NASDAQ:HLVX)

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

HLVX Stock Price History

HLVX Stock News Headlines

Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
HilleVax (NASDAQ:HLVX) Trading 4.6% Higher
HilleVax's (HLVX) "Buy" Rating Reiterated at HC Wainwright
Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
Recap: HilleVax Q4 Earnings
Aditya Kohli's Net Worth
HilleVax Appoints GSK's Sean McLoughlin As COO
See More Headlines
Receive HLVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HilleVax and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:HLVX
Fax
N/A
Employees
62
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$30.67
High Stock Price Target
$34.00
Low Stock Price Target
$28.00
Potential Upside/Downside
+80.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-123,570,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.48 per share

Miscellaneous

Free Float
35,139,000
Market Cap
$844.40 million
Optionable
Not Optionable
Beta
0.68
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Robert M. Hershberg M.D.Dr. Robert M. Hershberg M.D. (Age 62)
    Ph.D., President, CEO & Chairman of the Board
    Comp: $1.02M
  • Dr. Aditya Kohli Ph.D. (Age 35)
    Chief Business Officer & Director
    Comp: $782.44k
  • Mr. Shane A. Maltbie (Age 42)
    CFO & Treasurer
  • Mr. Sean McLoughlin (Age 52)
    Chief Operating Officer
  • Dr. Anju Chatterji Ph.D.
    Chief Technology Officer
  • Mr. Paul S. Bavier J.D. (Age 52)
    General Counsel, Secretary & Chief Administrative Officer
  • Ms. Astrid Borkowski M.D. (Age 54)
    Ph.D., Chief Medical Officer
  • Mr. Ozzie Berger
    Senior Vice President of Regulatory Affairs

HLVX Stock Analysis - Frequently Asked Questions

Should I buy or sell HilleVax stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HilleVax in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HLVX shares.
View HLVX analyst ratings
or view top-rated stocks.

What is HilleVax's stock price target for 2024?

3 Wall Street research analysts have issued twelve-month target prices for HilleVax's stock. Their HLVX share price targets range from $28.00 to $34.00. On average, they anticipate the company's share price to reach $30.67 in the next twelve months. This suggests a possible upside of 93.1% from the stock's current price.
View analysts price targets for HLVX
or view top-rated stocks among Wall Street analysts.

How have HLVX shares performed in 2024?

HilleVax's stock was trading at $16.05 at the start of the year. Since then, HLVX shares have decreased by 1.1% and is now trading at $15.88.
View the best growth stocks for 2024 here
.

Are investors shorting HilleVax?

HilleVax saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 474,900 shares, an increase of 10.2% from the February 29th total of 431,000 shares. Based on an average daily trading volume, of 127,400 shares, the short-interest ratio is presently 3.7 days. Approximately 3.2% of the company's shares are sold short.
View HilleVax's Short Interest
.

When is HilleVax's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our HLVX earnings forecast
.

What ETFs hold HilleVax's stock?

ETFs with the largest weight of HilleVax (NASDAQ:HLVX) stock in their portfolio include Morningstar US Small Growth (MSGR).Amplify Treatments, Testing and Advancements ETF (GERM).

When did HilleVax IPO?

HilleVax (HLVX) raised $200 million in an initial public offering on Friday, April 29th 2022. The company issued 11,765,000 shares at a price of $16.00-$18.00 per share.

Who are HilleVax's major shareholders?

HilleVax's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (3.81%), Vanguard Group Inc. (3.02%), Vanguard Group Inc. (3.02%), Catalys Pacific LLC (2.70%), Citadel Advisors LLC (1.50%) and Northern Trust Corp (0.51%). Insiders that own company stock include Aditya Kohli, Astrid Borkowski, Robert Hershberg and Shane Maltbie.
View institutional ownership trends
.

How do I buy shares of HilleVax?

Shares of HLVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:HLVX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners